PMID- 23853042
OWN - NLM
STAT- MEDLINE
DCOM- 20141027
LR  - 20211203
IS  - 1559-1182 (Electronic)
IS  - 0893-7648 (Linking)
VI  - 49
IP  - 1
DP  - 2014 Feb
TI  - Targeting the mTOR signaling network for Alzheimer's disease therapy.
PG  - 120-35
LID - 10.1007/s12035-013-8505-8 [doi]
AB  - The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine 
      kinase that can sense environmental stimuli such as growth factors, energy state, 
      and nutrients. It is essential for cell growth, proliferation, and metabolism, 
      but dysregulation of mTOR signaling pathway is also associated with a number of 
      human diseases. Encouraging data from experiments have provided sufficient 
      evidence for the relationship between the mTOR signaling pathway and Alzheimer's 
      disease (AD). Upregulation of mTOR signaling pathway is thought to play an 
      important role in major pathological processes of AD. The mTOR inhibitors such as 
      rapamycin have been proven to ameliorate the AD-like pathology and cognitive 
      deficits effectively in a broad range of animal models. Application of mTOR 
      inhibitors indicates the potential value of reducing mTOR activity as an 
      innovative therapeutic strategy for AD. In this review, we will focus on the 
      recent process in understanding mTOR signaling pathway and the vital involvement 
      of this signaling pathway in the pathology of AD, and discuss the application of 
      mTOR inhibitors as potential therapeutic agents for the treatment of AD.
FAU - Wang, Chong
AU  - Wang C
AD  - Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao 
      University, Qingdao, China.
FAU - Yu, Jin-Tai
AU  - Yu JT
FAU - Miao, Dan
AU  - Miao D
FAU - Wu, Zhong-Chen
AU  - Wu ZC
FAU - Tan, Meng-Shan
AU  - Tan MS
FAU - Tan, Lan
AU  - Tan L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130714
PL  - United States
TA  - Mol Neurobiol
JT  - Molecular neurobiology
JID - 8900963
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Alzheimer Disease/*drug therapy/*metabolism
MH  - Animals
MH  - Drug Delivery Systems/*methods/trends
MH  - Humans
MH  - Signal Transduction/drug effects/*physiology
MH  - Sirolimus/administration & dosage
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/*metabolism/physiology
EDAT- 2013/07/16 06:00
MHDA- 2014/10/28 06:00
CRDT- 2013/07/16 06:00
PHST- 2013/05/04 00:00 [received]
PHST- 2013/07/01 00:00 [accepted]
PHST- 2013/07/16 06:00 [entrez]
PHST- 2013/07/16 06:00 [pubmed]
PHST- 2014/10/28 06:00 [medline]
AID - 10.1007/s12035-013-8505-8 [doi]
PST - ppublish
SO  - Mol Neurobiol. 2014 Feb;49(1):120-35. doi: 10.1007/s12035-013-8505-8. Epub 2013 
      Jul 14.